EcoDrugPlus

Cholecystokinin B Receptor

Ensembl ID : ENSCATG00000036051
Gene Symbol: CCKBR
4 Cross references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSCATG00000031917
Gene Symbol: CETP
4 Cross references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSCATG00000004775
Gene Symbol: CHRM1
4 Cross references
104 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSCATG00000023535
Gene Symbol: CHRM2
4 Cross references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSCATG00000003262
Gene Symbol: CHRM4
4 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSCATG00000021242
Gene Symbol: CHRM5
4 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSCATG00000044554
Gene Symbol: CHRNA4
4 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSCATG00000019694
Gene Symbol: CHRNA7
4 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSCATG00000012048
Gene Symbol: CHRNB2
4 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSCATG00000038045
Gene Symbol: CHRNB4
4 Cross references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Chymase 1

Ensembl ID : ENSCATG00000033852
Gene Symbol: CMA1
4 Cross references
317 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSCATG00000004708
Gene Symbol: F2R
4 Cross references
330 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).